JP7361766B2 - ヒト免疫不全ウイルス複製の阻害剤 - Google Patents
ヒト免疫不全ウイルス複製の阻害剤 Download PDFInfo
- Publication number
- JP7361766B2 JP7361766B2 JP2021514019A JP2021514019A JP7361766B2 JP 7361766 B2 JP7361766 B2 JP 7361766B2 JP 2021514019 A JP2021514019 A JP 2021514019A JP 2021514019 A JP2021514019 A JP 2021514019A JP 7361766 B2 JP7361766 B2 JP 7361766B2
- Authority
- JP
- Japan
- Prior art keywords
- chloro
- methyl
- indazol
- difluorophenyl
- ethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862731196P | 2018-09-14 | 2018-09-14 | |
| US62/731,196 | 2018-09-14 | ||
| US201862733259P | 2018-09-19 | 2018-09-19 | |
| US62/733,259 | 2018-09-19 | ||
| PCT/IB2019/057710 WO2020053811A1 (en) | 2018-09-14 | 2019-09-12 | Inhibitors of human immunodeficiency virus replication |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022500425A JP2022500425A (ja) | 2022-01-04 |
| JPWO2020053811A5 JPWO2020053811A5 (https=) | 2022-08-09 |
| JP2022500425A5 JP2022500425A5 (https=) | 2022-08-09 |
| JP7361766B2 true JP7361766B2 (ja) | 2023-10-16 |
Family
ID=68240777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021514019A Active JP7361766B2 (ja) | 2018-09-14 | 2019-09-12 | ヒト免疫不全ウイルス複製の阻害剤 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20220089598A1 (https=) |
| EP (1) | EP3849982A1 (https=) |
| JP (1) | JP7361766B2 (https=) |
| WO (1) | WO2020053811A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021004593A (es) | 2018-10-24 | 2021-06-15 | Viiv Healthcare Uk No 5 Ltd | Inhibidores de la replicacion del virus de la inmunodeficiencia humana. |
| US20210395262A1 (en) * | 2018-10-24 | 2021-12-23 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| EP3873607B1 (en) * | 2018-10-29 | 2023-11-29 | VIIV Healthcare UK (No.5) Limited | Quinazolinyl-indazole derivatives and their use as inhibitors of human immunodeficiency virus replication |
| SG11202107145SA (en) | 2019-01-25 | 2021-08-30 | Univ Brown | Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders |
| TW202128648A (zh) * | 2019-10-04 | 2021-08-01 | 英商Viiv醫療保健英國(No 5)有限公司 | 人類免疫不全病毒複製之抑制劑 |
| WO2021070054A1 (en) * | 2019-10-08 | 2021-04-15 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| TWI902729B (zh) | 2019-11-28 | 2025-11-01 | 日商鹽野義製藥股份有限公司 | 以組合整合酶阻礙劑及抗hiv藥為特徵之hiv感染症的預防及治療用醫藥 |
| WO2024175044A2 (en) * | 2023-02-23 | 2024-08-29 | Ascletis Bioscience Co., Ltd. | Inhibitors of human immunodeficiency virus replication, method of making and method of using thereof |
| US20250042926A1 (en) | 2023-05-31 | 2025-02-06 | Gilead Sciences, Inc. | Therapeutic compounds for hiv |
| AR132951A1 (es) | 2023-06-15 | 2025-08-13 | Viiv Healthcare Uk No 5 Ltd | Métodos e intermedios para preparar compuestos |
| US12594276B2 (en) | 2024-02-05 | 2026-04-07 | Viiv Healthcare Uk (No. 5) Limited | Inhibitors of human immunodeficiency virus replication |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016504392A (ja) | 2013-01-09 | 2016-02-12 | ギリアード サイエンシーズ, インコーポレイテッド | 抗レトロウイルス剤としての(ヘテロ)アリールアセトアミド誘導体 |
| JP2016510038A (ja) | 2013-03-01 | 2016-04-04 | ギリアード サイエンシーズ, インコーポレイテッド | Hivの処置のためのアミド化合物 |
| JP2017525722A (ja) | 2014-08-29 | 2017-09-07 | ギリアード サイエンシーズ, インコーポレイテッド | 抗レトロウイルス剤 |
| JP2021534102A (ja) | 2018-08-09 | 2021-12-09 | ヴィーブ ヘルスケア ユーケー(ナンバー5)リミテッド | ヒト免疫不全ウイルス複製の阻害剤 |
| JP7301000B2 (ja) | 2017-05-02 | 2023-06-30 | ヴィーブ ヘルスケア ユーケー(ナンバー5)リミテッド | ヒト免疫不全ウイルス複製の阻害剤 |
| JP7307747B2 (ja) | 2018-04-11 | 2023-07-12 | ヴィーブ ヘルスケア ユーケー(ナンバー5)リミテッド | ヒト免疫不全ウイルス複製の阻害剤としての4-オキソ-3,4-ジヒドロキナゾリン化合物 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102464654B (zh) | 2010-11-12 | 2016-01-13 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
| EP2729448B1 (en) | 2011-07-06 | 2015-09-09 | Gilead Sciences, Inc. | Compounds for the treatment of hiv |
| CN102863512B (zh) | 2011-07-07 | 2016-04-20 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
| CA2897268C (en) | 2013-01-09 | 2018-12-04 | Gilead Sciences, Inc. | Therapeutic compounds for the treatment of viral infections |
| CA2896244C (en) | 2013-01-09 | 2017-07-04 | Gilead Sciences, Inc. | 5-membered heteroaryls and their use as antiviral agents |
| WO2015130966A1 (en) | 2014-02-28 | 2015-09-03 | Gilead Sciences, Inc. | Antiviral agents |
| WO2015130964A1 (en) | 2014-02-28 | 2015-09-03 | Gilead Sciences, Inc. | Therapeutic compounds |
| KR20230011471A (ko) | 2016-08-19 | 2023-01-20 | 길리애드 사이언시즈, 인코포레이티드 | Hiv 바이러스 감염의 예방적 또는 치유적 치료에 유용한 치료 화합물 |
| US10836746B2 (en) | 2018-02-15 | 2020-11-17 | Gilead Sciences, Inc. | Therapeutic compounds |
| WO2019161280A1 (en) | 2018-02-16 | 2019-08-22 | Gilead Sciences, Inc. | Methods and intermediates for preparing a therapeutic compound useful in the treatment of retroviridae viral infection |
-
2019
- 2019-09-12 WO PCT/IB2019/057710 patent/WO2020053811A1/en not_active Ceased
- 2019-09-12 EP EP19787072.8A patent/EP3849982A1/en active Pending
- 2019-09-12 US US17/272,377 patent/US20220089598A1/en not_active Abandoned
- 2019-09-12 JP JP2021514019A patent/JP7361766B2/ja active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016504392A (ja) | 2013-01-09 | 2016-02-12 | ギリアード サイエンシーズ, インコーポレイテッド | 抗レトロウイルス剤としての(ヘテロ)アリールアセトアミド誘導体 |
| JP2016510038A (ja) | 2013-03-01 | 2016-04-04 | ギリアード サイエンシーズ, インコーポレイテッド | Hivの処置のためのアミド化合物 |
| JP2017525722A (ja) | 2014-08-29 | 2017-09-07 | ギリアード サイエンシーズ, インコーポレイテッド | 抗レトロウイルス剤 |
| JP7301000B2 (ja) | 2017-05-02 | 2023-06-30 | ヴィーブ ヘルスケア ユーケー(ナンバー5)リミテッド | ヒト免疫不全ウイルス複製の阻害剤 |
| JP7307747B2 (ja) | 2018-04-11 | 2023-07-12 | ヴィーブ ヘルスケア ユーケー(ナンバー5)リミテッド | ヒト免疫不全ウイルス複製の阻害剤としての4-オキソ-3,4-ジヒドロキナゾリン化合物 |
| JP2021534102A (ja) | 2018-08-09 | 2021-12-09 | ヴィーブ ヘルスケア ユーケー(ナンバー5)リミテッド | ヒト免疫不全ウイルス複製の阻害剤 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020053811A1 (en) | 2020-03-19 |
| JP2022500425A (ja) | 2022-01-04 |
| WO2020053811A9 (en) | 2022-03-03 |
| US20220089598A1 (en) | 2022-03-24 |
| EP3849982A1 (en) | 2021-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7361766B2 (ja) | ヒト免疫不全ウイルス複製の阻害剤 | |
| JP7433303B2 (ja) | ヒト免疫不全ウイルス複製の阻害剤 | |
| JP7500555B2 (ja) | ヒト免疫不全ウイルス複製の阻害剤 | |
| ES2911948T3 (es) | Inhibidores de la replicación del virus de la inmunodeficiencia humana | |
| US20240374598A1 (en) | Inhibitors of human immunodeficiency virus replication | |
| JP2022509919A (ja) | ヒト免疫不全ウイルス複製の阻害剤 | |
| JP7532354B2 (ja) | ヒト免疫不全ウイルス複製の阻害剤 | |
| ES2969030T3 (es) | Derivados de quinazolinil-indazol y su uso como inhibidores de replicación de virus de inmunodeficiencia humana | |
| JP2022505841A (ja) | ヒト免疫不全ウイルス複製の阻害剤 | |
| TW202317574A (zh) | Cdk2抑制劑 | |
| JP6739516B2 (ja) | 呼吸器合胞体ウイルス阻害剤 | |
| ES2974657T3 (es) | Derivados de n-substituido-6-oxo-1,6-dihidropirimidina-2-ilo como inhibidores de la replicación del virus de inmunodeficiencia humana | |
| JP7545414B2 (ja) | ヒト免疫不全ウイルス複製阻害剤 | |
| JP7386230B2 (ja) | ヒト免疫不全ウイルス複製の阻害剤 | |
| CN115397424A (zh) | 人类免疫缺陷病毒复制的抑制剂 | |
| KR20220151655A (ko) | 인간 면역결핍 바이러스 복제의 억제제 | |
| EP4565584A1 (en) | 1h-pyrrolo[3,2-b]pyridine derivatives as irreversible inhibitors of mutant egfr for the treatment of cancer | |
| EA043730B1 (ru) | Ингибиторы репликации вируса иммунодефицита человека |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220801 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220801 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230803 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230905 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20231003 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7361766 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |